Efficient killing of planktonic and biofilm-embedded coagulase-negative staphylococci by bactericidal protein P128

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 8, 2017, Pages

  Poonacha, Nethravathi ^a   Nair, Sandhya ^a   Desai, Srividya ^a   Tuppad, Darshan ^a   Hiremath, Deepika ^a   Mohan, Thulasi ^a   Vipra, Aradhana ^a   Sharma, Umender ^a  

^a GangaGen Biotechnologies Pvt Ltd   (India)

Author keywords

Biofilms; Catheter related infections; Coagulase negative staphylococci; CoNS; CRBSI; Foreign body related infections; P128; Persisters; Stationary phase; Synergy

Indexed keywords

BACTERICIDE; CRYSTAL VIOLET; DAPTOMYCIN; LINEZOLID; P 128; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; COAGULASE; FUSION PROTEIN; P128 ANTISTAPHYLOCOCCAL CHIMERIC PROTEIN;

ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOFILM; COAGULASE NEGATIVE STAPHYLOCOCCUS; COLONY FORMING UNIT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; MIC90; MICROTITER PLATE ASSAY; MINIMUM BACTERICIDAL CONCENTRATION; NONHUMAN; PLANKTON; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS LUGDUNENSIS; CATHETER INFECTION; COMBINATION DRUG THERAPY; DRUG EFFECT; ENZYMOLOGY; FOREIGN BODY REACTION; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BIOFILMS; CATHETER-RELATED INFECTIONS; COAGULASE; DAPTOMYCIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FOREIGN-BODY REACTION; HUMANS; MICROBIAL SENSITIVITY TESTS; RECOMBINANT FUSION PROTEINS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS LUGDUNENSIS; VANCOMYCIN;

EID: 85026363454     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00457-17     Document Type: Article

References (48)

1. Gahlot R, Nigam C, Kumar V, Yadav G, Anupurba S. 2014. Catheter-related bloodstream infections. Int J Crit Illn Inj Sci. 4:162–167. https://doi.org/10.4103/2229-5151.134184.
2. von Eiff C, Jansen B, Kohnen W, Becker K. 2005. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 65:179–214. https://doi.org/10.2165/00003495-200565020-00003.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309–317. https://doi.org/10.1086/421946.
4. Zakhour R, Chaftari AM, Raad II. 2016. Catheter-related infections in patients with haematological malignancies: novel preventive and therapeutic strategies. Lancet Infect Dis 16:e241–e250. https://doi.org/10.1016/S1473-3099(16)30213-4.
5. Becker K, Heilmann C, Peters G. 2014. Coagulase-negative staphylococci. Clin Microbiol Rev 27:870–926. https://doi.org/10.1128/CMR.00109-13.
6. Czekaj T, Ciszewski M, Szewczyk EM. 2015. Staphylococcus haemolyticus—an emerging threat in the twilight of the antibiotics age. Microbiology 161:2061–2068. https://doi.org/10.1099/mic.0.000178.
7. Frank KL, Del Pozo JL, Patel R. 2008. From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis. Clin Microbiol Rev 21:111–133. https://doi.org/10.1128/CMR.00036-07.
8. May L, Klein EY, Rothman RE, Laxminarayan R. 2014. Trends in antibiotic resistance in coagulase-negative staphylococci in the United States, 1999 to 2012. Antimicrob Agents Chemother 58:1404–1409. https://doi.org/10.1128/AAC.01908-13.
9. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. 2013. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 68:4–11.
10. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318–1322. https://doi.org/10.1126/science.284.5418.1318.
11. Lewis K. 2008. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 322:107–131.
12. Stewart PS. 2015. Antimicrobial tolerance in biofilms. Microbiol Spectr 3:. https://doi.org/10.1128/microbiolspec.MB-0010.2014.
13. Singh R, Ray P, Das A, Sharma M. 2009. Role of persisters and small-colony variants in antibiotic resistance of planktonic and biofilm-associated Staphylococcus aureus: an in vitro study. J Med Microbiol 58:1067–1073. https://doi.org/10.1099/jmm.0.009720-0.
14. Conlon BP, Rowe SE, Gandt AB, Nuxoll AS, Donegan NP, Zalis EA, Clair G, Adkins JN, Cheung AL, Lewis K. 2016. Persister formation in Staphylococcus aureus is associated with ATP depletion. Nat Microbiol 18:16051. https://doi.org/10.1038/nmicrobiol.2016.51.
15. Cerca N, Martins S, Cerca F, Jefferson KK, Pier GB, Oliveira R, Azeredo J. 2005. Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry. J Antimicrob Chemother 56:331–336. https://doi.org/10.1093/jac/dki217.
16. Frank KL, Reichert EJ, Piper KE, Patel R. 2007. In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob Agents Chemother 51:888–895. https://doi.org/10.1128/AAC.01052-06.
17. Fredheim EG, Klingenberg C, Rohde H, Frankenberger S, Gaustad P, Flaegstad T, Sollid JE. 2009. Biofilm formation by Staphylococcus haemolyticus. J Clin Microbiol 47:1172–1180.
18. Yang S, Hay ID, Cameron DR, Speir M, Cui B, Su F, Peleg AY, Lithgow T, Deighton MA, Qu Y. 2015. Antibiotic regimen based on population analysis of residing persister cells eradicates Staphylococcus epidermidis biofilms. Sci Rep 5:18578. https://doi.org/10.1038/srep18578.
19. Yang H, Yu J, Wei H. 2014. Engineered bacteriophage lysins as novel anti-infectives. Front Microbiol 5:542.
20. Roach DR, Donovan DM. 2015. Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage 5:e1062590. https://doi.org/10.1080/21597081.2015.1062590.
21. Rodríguez-Rubio L, Martínez B, Donovan DM, Rodríguez A, García P. 2013. Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics. Crit Rev Microbiol 39:427–434. https://doi.org/10.3109/1040841X.2012.723675.
22. Paul VD, Rajagopalan SS, Sundarrajan S, George SE, Asrani JY, Pillai R, Chikkamadaiah R, Durgaiah M, Sriram B, Padmanabhan S. 2011. A novel bacteriophage tail-associated muralytic enzyme (TAME) from phage K and its development into a potent antistaphylococcal protein. BMC Microbiol 11:226.
23. Nair S, Desai S, Poonacha N, Vipra A, Sharma U. 2016. Antibiofilm activity and synergistic inhibition of S. aureus biofilms by bactericidal protein P128 in combination with antibiotics. Antimicrob Agents Chemother 60:7280–7289.
24. O’Flaherty S, Coffey A, Meaney W, Fitzgerald GF, Ross RP. 2005. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J Bacteriol 187:7161–7164. https://doi.org/10.1128/JB.187.20.7161-7164.2005.
25. Donovan DM, Lardeo M, Foster-Frey J. 2006. Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. FEMS Microbiol Lett 265:133–139. https://doi.org/10.1111/j.1574-6968.2006.00483.x.
26. Jun SY, Jung GM, Son JS, Yoon SJ, Choi YJ, Kang SH. 2011. Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. Antimicrob Agents Chemother 55:1764–1767.
27. Schuch R, Lee HM, Schneider BC, Sauve KL, Law C, Khan BK, Rotolo JA, Horiuchi Y, Couto DE, Raz A, Fischetti VA, Huang DB, Nowinski RC, Wittekind M. 2014. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J Infect Dis 209:1469–1478. https://doi.org/10.1093/infdis/jit637.
28. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Ólafsdóttir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH. 2016. Alternatives to antibiotics–a pipeline portfolio review. Lancet Infect Dis 16:239–251. https://doi.org/10.1016/S1473-3099(15)00466-1.
29. Zygmunt WA, Browder HP, Tavormina PA. 1968. Susceptibility of coagulase-negative staphylococci to lysostaphin and other antibiotics. Appl Microbiol 16:1168–1173.
30. Eng RH, Padberg FT, Smith SM, Tan EN, Cherubin CE. 1991. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother 35:1824–1828. https://doi.org/10.1128/AAC.35.9.1824.
31. Lechner S, Lewis K, Bertram R. 2012. Staphylococcus aureus persisters tolerant to bactericidal antibiotics. J Mol Microbiol Biotechnol 22:235–244. https://doi.org/10.1159/000342449.
32. Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, Beachey EH. 1985. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 22:996–1006.
33. Yang H, Zhang H, Wang J, Yu J, Wei H. 2017. A novel chimeric lysin with robust antibacterial activity against planktonic and biofilm methicillin-resistant Staphylococcus aureus. Sci Rep 7:40182. https://doi.org/10.1038/srep40182.
34. Drilling AJ, Cooksley C, Chan C, Wormald PJ, Vreugde S. 2016. Fighting sinus-derived Staphylococcus aureus biofilms in vitro with a bacteriophage-derived muralytic enzyme. Int Forum Allergy Rhinol 6:349–355. https://doi.org/10.1002/alr.21680.
35. Gutiérrez D, Ruas-Madiedo P, Martínez B, Rodríguez A, García P. 2014. Effective removal of staphylococcal biofilms by the endolysin LysH5. PLoS One 9:e107307. https://doi.org/10.1371/journal.pone.0107307.
36. Idelevich EA, von Eiff C, Friedrich AW, Iannelli D, Xia G, Peters G, Peschel A, Wanninger I, Becker K. 2011. In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin. Antimicrob Agents Chemother 55:4416–4419. https://doi.org/10.1128/AAC.00217-11.
37. Idelevich EA, Schaumburg F, Knaack D, Scherzinger AS, Mutter W, Peters G, Peschel A, Becker K. 2016. The recombinant bacteriophage endolysin HY-133 exhibits in vitro activity against different African clonal lineages of the Staphylococcus aureus complex, including Staphylococcus schweitzeri. Antimicrob Agents Chemother 60:2551–2553. https://doi.org/10.1128/AAC.02859-15.
38. Vipra AA, Desai SN, Roy P, Patil R, Raj JM, Narasimhaswamy N, Paul VD, Chikkamadaiah R, Sriram B. 2012. Antistaphylococcal activity of bacteriophage derived chimeric protein P128. BMC Microbiol 12:41. https://doi.org/10.1186/1471-2180-12-41.
39. Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF. 2015. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011–2014. Int J Antimicrob Agents 46:674–681. https://doi.org/10.1016/j.ijantimicag.2015.08.014.
40. Sugai M, Fujiwara T, Ohta K, Komatsuzawa H, Ohara M, Suginaka H. 1997. epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus. J Bacteriol 179:4311–4318. https://doi.org/10.1128/jb.179.13.4311-4318.1997.
41. Sundarrajan S, Raghupatil J, Vipra A, Narasimhaswamy N, Saravanan S, Appaiah C, Poonacha N, Desai S, Nair S, Bhatt RN, Roy P, Chikkamadaiah R, Durgaiah M, Sriram B, Padmanabhan S, Sharma U. 2014. Bacteriophage-derived CHAP domain protein, P128, kills Staphylococcus cells by cleaving interpeptide cross-bridge of peptidoglycan. Microbiology 160:2157–2169. https://doi.org/10.1099/mic.0.079111-0.
42. Uçkay I, Pittet D, Vaudaux P, Sax H, Lew D, Waldvogel F. 2009. Foreign body infections due to Staphylococcus epidermidis. Ann Med 41:109–119. https://doi.org/10.1080/07853890802337045.
43. Frank KL, Patel R. 2007. Poly-N-acetylglucosamine is not a major component of the extracellular matrix in biofilms formed by icaADBC-positive Staphylococcus lugdunensis isolates. Infect Immun 75:4728–4742. https://doi.org/10.1128/IAI.00640-07.
44. Oliveira F, Lima CA, Brás S, França Â, Cerca N. 2015. Evidence for inter- and intraspecies biofilm formation variability among a small group of coagulase-negative staphylococci. FEMS Microbiol Lett 362:.
45. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
46. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. NCCLS document M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
47. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1:1. https://doi.org/10.1093/jac/dkg301.
48. Mascio CT, Alder JD, Silverman JA. 2007. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 51:4255–4260. https://doi.org/10.1128/AAC.00824-07.